Ryanodine receptor 2

Ryanodine Receptor 2 (RyR2) is an intracellular calcium (Ca^2+) release channel predominantly found in the cardiac muscle. It plays a crucial role in the regulation of cardiac muscle contraction and relaxation by controlling the release of Ca^2+ from the sarcoplasmic reticulum (SR), an organelle that stores Ca^2+ inside cells. The RyR2 receptor is a key component in the excitation-contraction coupling process, a fundamental mechanism that translates electrical signals into mechanical contraction in heart muscle cells.

Structure[edit | edit source]

RyR2 is a large homotetrameric complex, meaning it is composed of four identical subunits. Each subunit contains a large cytoplasmic domain, which is involved in the regulation of the channel's activity, and a smaller transmembrane domain that forms the Ca^2+ conducting pore. The receptor is regulated by various factors, including calcium itself, cyclic adenosine monophosphate (cAMP), calmodulin, and phosphorylation by kinases such as protein kinase A (PKA).

Function[edit | edit source]

The primary function of RyR2 is to mediate the rapid release of Ca^2+ from the sarcoplasmic reticulum into the cytoplasm, a process that is essential for cardiac muscle contraction. Upon electrical stimulation of the heart muscle cell, Ca^2+ enters the cell through L-type calcium channels located in the cell membrane. This influx of Ca^2+ triggers the RyR2 channels to open, resulting in a much larger release of Ca^2+ from the SR, a process known as calcium-induced calcium release (CICR). The increase in cytoplasmic Ca^2+ concentration initiates the contraction of the heart muscle. During relaxation, Ca^2+ is pumped back into the SR by the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA), allowing the muscle to relax.

Clinical Significance[edit | edit source]

Mutations in the RyR2 gene are associated with several cardiac disorders, including catecholaminergic polymorphic ventricular tachycardia (CPVT), a condition characterized by abnormal heart rhythms that can lead to fainting, seizures, or sudden death, especially during physical activity or emotional stress. Other conditions linked to RyR2 mutations include arrhythmogenic right ventricular cardiomyopathy (ARVC) and some forms of familial atrial fibrillation.

Research and Therapeutics[edit | edit source]

Given its critical role in cardiac function, RyR2 is a target for therapeutic intervention in various heart conditions. Researchers are exploring drugs that can modulate RyR2 activity to treat heart failure and arrhythmias. For example, drugs that stabilize the closed state of the channel may prevent abnormal calcium leaks that contribute to heart failure and arrhythmias.